Monopar FY2022 net loss $10.5M; Validive interim readout due next week; camsirubicin dose-escalation continues

Monopar Therapeutics

Net loss FY2022 $10.5M ($0.83/share) vs $9.1M ($0.73/share) in 2021; cash $13.1M.
Validive Phase 2b/3 VOICE trial interim analysis go/no-go readout expected by end of next week.
Camsirubicin Phase 1b enrolling 5th dose level (650 mg/m²); no cardiotoxicity, 75% no hair loss.
CFO Kim Tsuchimoto appointed to board; board size increased to six.
Current funds expected to cover camsirubicin topline results by end 2023; additional funding sought within 12 months.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Monopar Therapeutics reported financial results for fourth quarter and full year ended December 31, 2022.

Period: fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 23, 2023, Monopar Therapeutics Inc. issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Monopar Therapeutics filing history →

Source: SEC EDGAR

accession 0001654954-23-003383

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.